NCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
Clinical Trials
11 trialsNCT06904235 2025-07-28
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Helsinn Healthcare SA
Phase 2 Recruiting
NCT01836705 2025-03-05
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03204279 2024-06-25
CINV
Helsinn Healthcare SA
Phase 2 Completed
NCT05199818 2023-01-20
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
Xiamen LP Pharmaceutical Co., Ltd
Phase 3 Unknown
NCT01363479 2021-09-22
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT02557035 2018-06-20
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT00684463 2017-05-16
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00306735 2016-12-05
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
Eisai Inc.
Phase 2 Completed
NCT01909856 2015-12-04
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT01339260 2014-11-26
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed